Role of paraoxonase-1 in CYP2C19 loss-of-function carriers

Thrombosis Research

Volumn 133, Issue 3, 2014, Pages 519-

  Daali, Y ^a   Reny, J L ^a   Fontana, P ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ARYLDIALKYLPHOSPHATASE; TICLOPIDINE; UNSPECIFIC MONOOXYGENASE;

ANALOGS AND DERIVATIVES; FEMALE; GENETICS; HUMAN; MALE; METABOLISM; THROMBOSIS;

ARYL HYDROCARBON HYDROXYLASES; ARYLDIALKYLPHOSPHATASE; ASPIRIN; FEMALE; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; THROMBOSIS; TICLOPIDINE;

EID: 84893921524     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2013.12.034     Document Type: Letter

References (8)

1. R. Nishio et al. Paraoxonase-1 activity affects the clopidogrel response in CYP2C19 loss-of-function carriers Thromb Res 132 5 2013 558 564
2. P.M. Dansette, J. Rosi, G. Bertho, and D. Mansuy Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer Chem Res Toxicol 25 2 2012 348 356
3. V. Ancrenaz et al. Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability Curr Drug Metab 11 8 2010 667 677
4. V. Ancrenaz et al. The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitro Br J Pharmacol 166 8 2012 2362 2370
5. P.M. Dansette, J. Rosi, G. Bertho, and D. Mansuy Paraoxonase-1 and clopidogrel efficacy Nat Med 17 9 2011 1040 1041 [author reply 1042-4]
6. P. Fontana et al. Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study J Thromb Haemost 9 8 2011 1664 1666
7. J.L. Reny, C. Combescure, Y. Daali, and P. Fontana Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis J Thromb Haemost 10 7 2012 1242 1251
8. A.L. Frelinger III et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function J Am Coll Cardiol 61 8 2013 872 879